USA flag logo/image

An Official Website of the United States Government

Anti-inflammatory and Mitotic Properties of Non-hormonal Steroids in Lung…

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2010 / STTR
Agency Tracking Number:
R41HL104939
Solicitation Year:
2010
Solicitation Topic Code:
NHLBI
Solicitation Number:
PA09-081
Small Business Information
REVERAGEN BIOPHARMA, INC.
9700 GREAT SENECA HWY, STE 160 ROCKVILLE, MD 20850-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2010
Title: Anti-inflammatory and Mitotic Properties of Non-hormonal Steroids in Lung Epithel
Agency: HHS
Contract: 1R41HL104939-01
Award Amount: $178,857.00
 

Abstract:

DESCRIPTION (provided by applicant): Asthma is a very common lung condition in children, and incidence is increasing in the US particularly in urban and minority populations. The standard of care for asthmatics is inhaled steroid, although clinical response is variable. The mechanism of efficacy of steroids in asthma is thought to be via anti-inflammatory pathways, although other anti-inflammatory drugs have generally shown poor efficacy. Here, we describe a new series of drugs that show promise in the treatment of asthma symptoms. The VBP series shows lack of competitive binding to the glucocorticoid receptor, yet retains strong transrepression (signaling) activities of glucocorticoids indicative of a dissociation of glucocorticoid sub-activities (transcriptional vs. signaling) which is hypothesized to maintain the beneficial effects while reducing the metabolic side effects of tradition steroid therapies (e.g. prednisone). We present preliminary data showing that Dexamethasone resynchronizes the cell cycleof asthmatic primary differentiated bronchial epithelial cells and dramatically reduces cytokine production from these cells. VBP drugs retain the ability of glucocorticoids to resynchronize the cell cycle in these same primary bronchial cells. We show extensive data on NF-(B transactivation in muscle cells, where VBP drugs retain potency in NF-(B inhibition, similar to prednisone. This STTR application is to characterize 20 VBP derivatives in lung-derived cells with regards to NF-(B inhibition, cell cyclesynchronization, and cytokine production. The deliverable is to identify lead compounds from the 20 that will be taken into in vivo testing in asthmatic mouse models, and subsequent toxicology and clinical trials. PUBLIC HEALTH RELEVANCE: Syntheticglucocorticoids are a standard treatment for Asthma. Asthma has become considerably more prevalent and severe in the United States during the last 30 years with approximately 83 in 1,000 children affected. The greater efficacy of synthetic glucocorticoidshas made them the standard anti-inflammatory therapy for the treatment of asthma for decades. However, there is a subset of patients that do not respond to steroid therapies in addition to the side effects of chronic use of steroids for those patients thatare responsive. The aim of this study is to perform in vitro screening of newly developed non-hormonal steroids for the treatment of asthma. The 5 most optimal compounds will be tested in an ex vivo model with the goal of identifying 2-3 lead compounds totake into the mouse model for asthma.

Principal Investigator:

Erica Reeves
240-401-9434
erica.reeves@vbpharm.com

Business Contact:

Erica Reeves
240-401-9434
erica.reeves@vbpharm.com
Small Business Information at Submission:

REVERAGEN BIOPHARMA, INC.
9700 GREAT SENECA HWY, STE 160 ROCKVILLE, MD 20850-

EIN/Tax ID: 126380841
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Research Institution Information:
Children'S National Medical Center
111 MICHIGAN AVENUE NW
WASHINGTON, DC 20010-
Contact: